World’s First Oral Vaccine For Bacteria Linked To Gastric Cancer
China’s Ministry of Science and Technology confirmed that the country has pioneered an oral vaccine associated with gastric cancer. The vaccine will shield people from infection caused by Helicobacter pylori. This particular bacterium nestles in the stomach and cause formation of duodenal, gastric ulcers and stomach cancer. The Science and Technology Ministry has suggested that the oral vaccine is a vanguard formula is the first of its kind to pass through large-scale phase-3 clinical trials and become a ratified medicine.
China’s Food and Drug Administration has already classified the medicine as “first-grade new medicine”. A research squad from Chongqing-based Third Military Medical University has put forth the vaccine. Professor Zou Quanming lead the team. Consolidated effort of one and a half decade has resulted in the preparation of this drug. While being researched upon, the medicine had already cornered 8 national patents and presently holds complete rights to it’s intellectual property.
With a shielding rate of nearly 72.1 percent against Helicobacter pylori, the vaccine would soon be commercialized. Already, Hp is a curse for China afflicting nearly 600 million people, statistic shows that around 200000 people die of stomach cancer each year.